Investors hoping that tax cuts and aggressive government spending plans will add another leg to the bull market likely are going to be disappointed, Morgan Stanley argues in an analysis that contends the end of big returns is near.
Our Top Pick for more speculative investors is a biopharmaceutical company that discovers, develops, and commercializes oral antivirals in areas of unmet medical needs in the United States, explains Bill Mathews, editor of The Cheap Investor.
The lead product candidate from Chimerix (CMRX) is brincidofovir (CMX001), a nucleotide analog.
The drug is in Phase III clinical trials....More>>>
Sometimes I discuss stocks which sit out of my comfort zone, simply because they have a few characteristics which could be of interest to any kind of investor but don’t necessarily fit my portfolio. For example a blue chip stock which has features of positive capital gains combined with interesting dividend. In this case I am talking about Accenture (NYSE:ACN). A little bit more than a year....More>>>
Retirement comes as a welcome relief for well-prepared couples: a chance to travel, adopt new hobbies, and (finally) sleep in. It’s easy to overlook logistical details amid the excitement of beginning a new phase, and timing is as logistical as it gets.
As most couples do, you’ve probably been referring to D-Day as an all-encompassing “when ‘we’ retire,”....More>>>
Lands’ End (NASDAQ:LE) CMO Gill Brown Hong bought 1,525 shares of the company’s stock in a transaction on Friday, April 13th. The shares were bought at an average price of $22.20 per share, with a total value of $33,855.00. Following the completion of the transaction, the chief marke
Enbridge Energy, Limited Partnership (NYSE:EEP) had its target price lowered by Barclays from $16.00 to $11.00 in a research report sent to investors on Tuesday morning, Marketbeat reports. The brokerage currently has an equal weight rating on the pipeline company’s stock.